This content is PDF only. Please click on the PDF icon to access.
One of the most intriguing problems in cancer therapy is why drugs that affect ubiquitous enzyme systems have any predilection for tumor cells. Classical biochemical techniques involving the identification of target enzymes have only rarely demonstrated differences between the normal and the neoplastic cell. Although there has been considerable interest in cell-control mechanisms based on elegant work in bacterial genetics, biochemists and pharmacologists are only recently paying some attention to the cell cycle as a potential "control mechanism." The kinetic restrictions imposed on the rhythmic appearance and disappearance of enzymes amenable to chemotherapeutic attack may well result in a selective
The Cell Cycle and Cancer.. Ann Intern Med. 1972;76:156. doi: https://doi.org/10.7326/0003-4819-76-1-156_1
Download citation file:
Published: Ann Intern Med. 1972;76(1):156.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use